Compound 1 was also found to be involved with Akt, mTOR, and MEK-ERK pathways in renal carcinoma cells [45] or the inactivation of EGFR-related pathways in bladder cancer cells [47]. Here, MAP2K7 is linked to urinary bladder carcinoma.